Go Back Menu
Close
Formulations
Catering to Every
Patient’s Needs
Patient’s Needs
Mankind Pharma is dedicated to the development, manufacturing, and commercialization of a diverse range of pharmaceutical formulations. Our focus lies in addressing both acute and chronic therapeutic areas, with a strategic approach to introduce multiple brands within each therapeutic segment. This enables us to cater to the diverse needs of a wide patient population, offering tailored solutions for optimal treatment outcomes.
Our Therapeutic
Portfolio
Portfolio
Our portfolio of 500+ products comprises a broad range of formulations across various acute and chronic therapeutic areas.
DOWNLOAD PRODUCT LIST 
Anti-infectives
15%
Anti-infectives portfolio share in domestic sales
cardiovascular
15%
Cardiovascular portfolio share in domestic sales
Gastrointestinal
10%
Gastrointestinal portfolio share in domestic sales
Respiratory
9%
Respiratory portfolio share in domestic sales
Vitamins / Minerals / Nutrients
8%
VMN portfolio share in domestic sales
Anti-Diabetic
9%
Anti-diabetic portfolio share in domestic sales
Gynaecology
8%
Gynaecology portfolio share in our domestic sales
Dermatology
5%
Dermatology portfolio share in domestic sales
Pain / Analgesics
4%
Pain / Analgesics portfolio share in domestic sales
Neuro / CNS
3%
Neuro/CNS portfolio share in domestic sales
Novel Drug
Therapies
Therapies
Beyond complex generics, we are actively advancing novel drug therapies to meet the evolving needs of patients globally. We are particularly focused on therapeutic areas with unmet needs, such as autoimmune diseases and non-alcoholic steatohepatitis (NASH).
Anti-Diabetic NCE
Our pipeline includes an Investigational New Drug (IND) for an anti-diabetic NCE molecule, which is currently undergoing Phase I clinical trials. This promising new drug is designed to help manage diabetes in a way that current therapies do not fully address, offering a novel treatment approach to millions of patients worldwide.
Autoimmune Diseases & NASH
We are also exploring two promising NCE molecules aimed at treating autoimmune diseases and non-alcoholic steatohepatitis (NASH), which are currently in the pre-clinical stage. These therapies have the potential to significantly improve patient outcomes in these complex conditions that affect millions globally.